Statins as immunomodulators

Transplant Immunology

Volumn 9, Issue 2-4, 2002, Pages 197-200

  Mach, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Immunology; MHC II; Statins (HMG CoA reductase inhibitors); Transplantation

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CYCLOHEXIMIDE; DACTINOMYCIN; FLUINDOSTATIN; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; ISOPRENOID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEVINOLIN; PRAVASTATIN; RECOMBINANT GAMMA INTERFERON; SIMVASTATIN; HLA ANTIGEN CLASS 2; IMMUNOSUPPRESSIVE AGENT; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN; TRANSACTIVATOR PROTEIN;

ANTIGEN EXPRESSION; APOPTOSIS; CELL STIMULATION; CELL TYPE; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ENDOTHELIUM CELL; GRAFT REJECTION; GRAFT SURVIVAL; HEART DISEASE; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MEDICAL PRACTICE; OUTCOMES RESEARCH; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; ANIMAL; BIOSYNTHESIS; GENETICS; PHYSIOLOGY; REVIEW;

ANIMALS; HEART TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; NUCLEAR PROTEINS; TRANS-ACTIVATORS;

EID: 0036583733     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(02)00030-8     Document Type: Conference Paper

References (38)

1. Current perspectives on statins
2. The use of statins in acute coronary syndromes: The mechanisms behind the outcomes
3. Statin therapy: Where are we? Where do we go next?
4. The evolving role of statins in the management of atherosclerosis
5. Lowering LDL cholesterol: Questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting
6. Non-lipid-related effects of statins
7. New insights into the pharmacodynamic and pharmacokinetic properties of statins
8. Pleiotropic effects of statins
9. Statins inhibit leukocyte recruitment: New evidence for their anti-inflammatory properties
10. Pleiotropic effects of statins: Do they matter?
11. Post-translational modification of low molecular mass GTP-binding proteins by isoprenoid
12. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
13. Regulation of endothelial NO production by Rho GTPase
14. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription
15. Procoagulant and proinflammatory activity in acute coronary syndromes
16. Statins and monocytes
17. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
18. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia
19. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: Role of nitric oxide
20. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin
21. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture
22. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells
23. Direct vascular effects of HMG-CoA reductase inhibitors
24. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
25. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
26. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis
27. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia
28. Pravastatin: An antithrombotic effect independent of the cholesterol-lowering effect
29. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins
30. Lovastatin Modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: Role of geranylgeranylation and Rho proteins
31. Effect of pravastatin on outcomes after cardiac transplantation
32. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial
33. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)
34. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA
35. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA
36. Quantitative control of MHC class II expression by the transactivator CIITA
37. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1
38. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site